Skip to main content

Managing JDM with Calcinosis

Aug 19, 2022 5:00 am

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.

  1. CDC report of fungal infx in US 2019 - coccidioidomycosis (20,061), histoplasmosis (1,124) & blastomycosis (240). Most Cocci cases (97%) AZ & CA; most Blasto (75%) in MN &WI; most Histo in IL (26%), but also MN, MI, WI, IN, LA, AR.

  2. Medicare study of 10,868 Hospitalized lupus pts. Looking at age groups. 30 d rehospitalization higher in young adult LE (36%) - 40% higher than those without LE, 85% higher older LE. Rehospitalization higher with Longer hosp stay & higher comorbidity.

  3. Urine-soluble CD163 as a biomarker in #SLE: usCD163 significantly higher w/ active lupus nephritis & correlates w/ UPCR, disease activity, anti-dsDNA Ab levels and a higher chronic kidney disease stage.

  4. Drug-Induced Lupus from Proton Pump Inhibitors

  5. MSK US in Gout? 71 gout pts on ULT followed x 1yr, 42% had at least one flare (median=2). Baseline US showing MSU deposits & inflammation significantly assoc w/ with # Flares (MSU score RR 1.17; power Doppler score RR 1.29)

  6. Gout T2T: Rheumatology societies target urate <5 mg/dl (0.30 mmol/l) or <6 mg/dl (<0.36 mmol/l) - below point of urate saturation -->MSU crystal dissolution. Achieving target reduces flares & tophi; but these clinical benefits take time.

  7. Study of 209 Early RA (<1yr) pts found 23 (11%) with Drug Free Remission (DFR) after 74 mos of F/U; DFR maintained x 48 mo (18–82). DFR was assoc w/ early persistence on Therapy (HR 3.84). Adhering to prescribed treatment may lead to DFR

  8. Recurrence of axSpA in 1st-degree relatives (FDR) probands w/ 35-yrs F/U. From 363 AS probands & 806 FDR, 27.1% of B27(+) FDR developed axSpA; 18.2% from AS probands; 4% from nr-axSpA probands. Recurrence higher with B27+ probands

  9. Axial PsA frequency? Study of Derm identified PSO adults w/ chronic LBP, onset <45 yrs, not Rx w/ DMARDs--> 100 pts referred to Rheumatology; 14 pts dx w/ axPsA, 5 w/ peripheral PsA, & 3 w/ both axial & peripheral PsA

  10. Cochrane review of Stem cell transplantation in systemic sclerosis (3RCTs w/ 125 pts). Non‐myeloablative & myeloablative selective HSCT had moderate evidence for improved survival, skin thickness & function. But these had high Serious AE rates.

  11. Rituximab Efficacy in Systemic Sclerosis

  12. Low Dose IL-2 Therapy in SLE   

  13. Melatonin Use Growing, Inappropriate & Potentially Unsafe

  14. Ask Cush Anything – JDM and Calcinosis Dr. Fawzi Mazen

    Are you a fan of the RheumNow podcast? Please rate, like and review us wherever you get your podcast. We'd appreciate it!

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.